Healthcare Resource Utilization and Costs Among Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients: A Retrospective Cohort Study Using Contemporary US Claims

被引：0
|
作者：
Huntington, Scott F. [1 ]
Chang, Hsien-Yen [2 ]
Fu, Alex Z. [2 ,3 ]
Loefgren, Christina [4 ]
Lu, Xiaoxiao [5 ]
机构：
[1] Yale Univ, Div Hematol, New Haven, CT USA
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] Georgetown Univ, Med Ctr, Washington, DC USA
[4] Janssen Global Serv LLC, Raritan, NJ USA
[5] Janssen Sci Affairs LLC, Real World Value & Evidence, Horsham, PA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181909
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] HEALTHCARE RESOURCE UTILIZATION AND COSTS IN A DAPA-CKD-LIKE POPULATION USING A CONTEMPORARY US HEALTHCARE COHORT.
    Olufade, Tope
    Lamerato, Lois
    Sanchez, Juan Jose Garcia
    Jiang, Like
    Huang, Joanna
    Nolan, Stephen
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1116 - 1116
  • [42] Evaluation of Healthcare Resource Utilization and Costs Among Patients with Chronic Myeloid Leukemia after Disease Progression
    Jabbour, Elias
    Lin, Jay
    Siegartel, Lisa R.
    Lingohr-Smith, Melissa
    Menges, Brandy
    Makenbaeva, Dinara
    BLOOD, 2016, 128 (22)
  • [43] Incidence of CDI in a Cohort of US Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy
    Lurienne, Lise
    Le Bescop, Clement
    Buffet, Renaud
    Bandinelli, Pierre-Alain
    BLOOD, 2020, 136
  • [44] Incidence of CDI in a Cohort of US Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy
    Lurienne, Lise
    Le Bescop, Clement
    Buffet, Renaud
    Bandinelli, Pierre-Alain
    BLOOD, 2020, 136
  • [45] Comparing medication persistence, healthcare resource utilization and costs among newly diagnosed, newly treated patients using dabigatran vs warfarin.
    Iorga, Serban R.
    Bancroft, Tim
    Lim, Jonathan
    Wang, Cheng
    Sander, Stephen D.
    Swindle, Jason P.
    PHARMACOTHERAPY, 2014, 34 (06): : E76 - E76
  • [46] Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US)
    Bell, Jill A.
    Galaznik, Aaron
    Murty, Sharanya
    Pollack, Megan
    Ogbonnaya, Augustina
    Eaddy, Michael T.
    Fram, Robert J.
    Faller, Douglas V.
    Kota, Vamsi
    BLOOD, 2017, 130
  • [47] Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed Z. H.
    Laliberte, Francois
    BLOOD, 2022, 140 : 10911 - 10912
  • [48] A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Walker, Alison R.
    Vasu, Sumithra
    Mims, Alice S.
    Walsh, Katherine J.
    Behbehani, Gregory K.
    Blachly, James S.
    Vittorio, Molly
    Zhao, Qiuhong
    Ruppert, Amy S.
    Orwick, Shelley
    Ranganathan, Parvathi
    Byrd, John C.
    Blum, William
    Garzon, Ramiro
    BLOOD, 2016, 128 (22)
  • [49] A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (RR) FLT3-ITD acute myeloid leukemia (AML).
    Daver, Naval Guastad
    Zhang, Weiguo
    Graydon, Richard
    Dawra, Vikas
    Xie, Jingdong
    Kumar, Prasanna
    Andreeff, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study
    Zhang, Jian
    Song, Baoquan
    Liu, Yin
    Wu, De-Pei
    Qiu, Huiying
    BLOOD, 2023, 142
12345